Leavenworth’s contributions bridge laboratory research with clinical applications, paving the way for innovative cancer ...
targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information ...
We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...
targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information ...
targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information ...
Taken together, our study demonstrated that IL-12 directly activated both STAT1 and STAT4 and regulated BCL6 and TBX21 gene by alteration of histone modifications, resulting in differentiation of ...
LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought—with the potential for new therapeutic approaches. As the researchers demonstrate ...
NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback